Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the multicenter evaluation of single high-dose bolus tirofiban versus abciximab with sirolimus-eluting stent or bare-metal stent in acute myocardial infarction study trial

Giuseppe Ferrante, Patrizia Presbitero, Elena Corrada, Gianluca Campo, Leonardo Bolognese, Corrado Vassanelli, Salvatore Colangelo, Nicoletta De Cesare, Alfredo E. Rodriguez, Ezio Bramucci, Raul Moreno, Tommaso Piva, Imad Sheiban, Giampaolo Pasquetto, Francesco Prati, Marco S. Nazzaro, Roberto Ferrari, Marco Valgimigli

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: We assessed the relation between female sex and sirolimus-eluting stent (SES) use on long-term outcomes in acute myocardial infarction. Background: There are no data on sex-specific differences in long-term benefit of SES use compared with bare-metal stent (BMS) use among patients undergoing primary percutaneous coronary interventions. Methods: We performed a post hoc analysis of the MULTISTRATEGY trial. Hazard ratios (HRs) of events with 95% CI for sex and stent type were computed using Cox proportional regression with adjustment for confounders. Results: A total of 744 patients, 64 years old (55-73 years old), 179 (24.1%) women, were enrolled. After a follow-up of 1,080 days, SES use was associated with a significant reduction of major adverse cardiovascular events, that is, the composite of all-cause death, reinfarction, or clinically driven target vessel revascularization (TVR) (13.9% vs 23.6%, adjusted HR 0.62, 95% CI 0.41-0.94, P =.026) and of TVR (6.1% vs 15.1%, adjusted HR 0.35, 95% CI 0.19-0.63, P

Original languageEnglish
Pages (from-to)104-111
Number of pages8
JournalAmerican Heart Journal
Volume163
Issue number1
DOIs
Publication statusPublished - Jan 2012

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the multicenter evaluation of single high-dose bolus tirofiban versus abciximab with sirolimus-eluting stent or bare-metal stent in acute myocardial infarction study trial'. Together they form a unique fingerprint.

Cite this